{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:48:01Z","timestamp":1780530481569,"version":"3.54.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage\u2009\u2265\u2009III. Stage I\u2013III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.<\/jats:p>","DOI":"10.1007\/s12094-020-02539-9","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T14:03:09Z","timestamp":1614693789000},"page":"948-960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["SEOM clinical guideline for the management of cutaneous melanoma (2020)"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-7485","authenticated-orcid":false,"given":"M.","family":"Majem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Marquez-Rodas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mujika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"P\u00e9rez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de la Cruz-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gonzalez-Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"issue":"6","key":"2539_CR1","first-page":"348","volume":"170","author":"PG Shekelle","year":"1999","unstructured":"Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Developing clinical guidelines. West J Med. 1999;170(6):348\u201351.","journal-title":"West J Med"},{"issue":"Suppl","key":"2539_CR2","doi-asserted-by":"publisher","first-page":"19S","DOI":"10.1053\/bbmt.2001.v7.pm11777100","volume":"7","author":"CA Dykewicz","year":"2001","unstructured":"Dykewicz CA. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. Biol Blood Marrow Transpl. 2001;7(Suppl):19S\u201322S.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2539_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejca.2019.11.014","volume":"126","author":"C Garbe","year":"2020","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics\u2014update 2019. Eur J Cancer (Oxford, England: 1990). 2020;126:141\u201358.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"6","key":"2539_CR4","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jid.2016.01.035","volume":"136","author":"DC Whiteman","year":"2016","unstructured":"Whiteman DC, Green AC, Olsen CM. The Growing Burden of Invasive Melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol. 2016;136(6):1161\u201371.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2539_CR5","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1111\/jdv.15565","volume":"33","author":"E Gutierrez-Gonzalez","year":"2019","unstructured":"Gutierrez-Gonzalez E, Lopez-Abente G, Aragones N, Pollan M, Pastor-Barriuso R, Sanchez MJ, et al. Trends in mortality from cutaneous malignant melanoma in Spain (1982\u20132016): sex-specific age-cohort-period effects. J Eur Acad Dermatol Venereol. 2019;33(8):1522\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"2539_CR6","first-page":"1617","volume":"20","author":"J Rubio-Casadevall","year":"2018","unstructured":"Rubio-Casadevall J, Puig-Vives M, Puigdemont M, Vilardell L, Carbo-Bague A, Marcos-Gragera R, et al. Patterns of increased incidence and survival of cutaneous melanoma in Girona (Spain) 1994\u20132013: a population-based study. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mexico. 2018;20(12):1617\u201325.","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mexico"},{"key":"2539_CR7","unstructured":"Cifras del cancer en Espa\u00f1a. 2020. https:\/\/seom.org\/dmcancer\/cifras-del-cancer\/."},{"issue":"2","key":"2539_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R","volume":"73","author":"JM Elwood","year":"1997","unstructured":"Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer. 1997;73(2):198\u2013203.","journal-title":"Int J Cancer"},{"issue":"14","key":"2539_CR9","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.ejca.2005.03.034","volume":"41","author":"S Gandini","year":"2005","unstructured":"Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer (Oxford, England: 1990). 2005;41(14):2040\u201359.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"1","key":"2539_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2004.10.015","volume":"41","author":"S Gandini","year":"2005","unstructured":"Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: Common and atypical naevi. Eur J Cancer (Oxford, England: 1990). 2005;41(1):28\u201344.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"7","key":"2539_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/cup.13689","volume":"47","author":"A Toussi","year":"2020","unstructured":"Toussi A, Mans N, Welborn J, Kiuru M. Germline mutations predisposing to melanoma. J Cutan Pathol. 2020;47(7):606\u201316.","journal-title":"J Cutan Pathol"},{"issue":"3","key":"2539_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1200\/JCO.2010.28.7078","volume":"29","author":"AC Green","year":"2011","unstructured":"Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol. 2011;29(3):257\u201363.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2539_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1001\/archderm.134.1.103-a","volume":"134","author":"JJ Grob","year":"1998","unstructured":"Grob JJ, Bonerandi JJ. The \u2018ugly duckling\u2019 sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol. 1998;134(1):103\u20134.","journal-title":"Arch Dermatol"},{"issue":"3","key":"2539_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1470-2045(02)00679-4","volume":"3","author":"H Kittler","year":"2002","unstructured":"Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 2002;3(3):159\u201365.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2539_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jaad.2019.08.074","volume":"82","author":"A Lallas","year":"2020","unstructured":"Lallas A, Apalla Z, Kyrgidis A, Papageorgiou C, Boukovinas I, Bobos M, et al. Second primary melanomas in a cohort of 977 melanoma patients within the first 5\u00a0years of monitoring. J Am Acad Dermatol. 2020;82(2):398\u2013406.","journal-title":"J Am Acad Dermatol"},{"key":"2539_CR16","first-page":"CD013190","volume":"12","author":"J Dinnes","year":"2018","unstructured":"Dinnes J, Deeks JJ, Saleh D, Chuchu N, Bayliss SE, Patel L, et al. Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults. Cochrane Database Syst Rev. 2018;12:CD013190.","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"2539_CR17","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u201392.","journal-title":"CA Cancer J Clin"},{"issue":"7666","key":"2539_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature23291","volume":"548","author":"Z Yao","year":"2017","unstructured":"Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017;548(7666):234\u20138.","journal-title":"Nature"},{"issue":"3","key":"2539_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40257-018-0414-1","volume":"20","author":"D Meng","year":"2019","unstructured":"Meng D, Carvajal RD. KIT as an oncogenic driver in melanoma: an update on clinical development. Am J Clin Dermatol. 2019;20(3):315\u201323.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"2539_CR20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/1878-0261.12050","volume":"11","author":"H Cirenajwis","year":"2017","unstructured":"Cirenajwis H, Lauss M, Ekedahl H, Torngren T, Kvist A, Saal LH, et al. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. Mol Oncol. 2017;11(4):438\u201351.","journal-title":"Mol Oncol"},{"issue":"2","key":"2539_CR21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1470-2045(15)00482-9","volume":"17","author":"AJ Hayes","year":"2016","unstructured":"Hayes AJ, Maynard L, Coombes G, Newton-Bishop J, Timmons M, Cook M, et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol. 2016;17(2):184\u201392.","journal-title":"Lancet Oncol"},{"issue":"14","key":"2539_CR22","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1200\/JCO.2009.27.1627","volume":"28","author":"CM Balch","year":"2010","unstructured":"Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28(14):2452\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2539_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0002-9610(00)00533-X","volume":"181","author":"CL Nguyen","year":"2001","unstructured":"Nguyen CL, McClay EF, Cole DJ, O\u2019Brien PH, Gillanders WE, Metcalf JS, et al. Melanoma thickness and histology predict sentinel lymph node status. Am J Surg. 2001;181(1):8\u201311.","journal-title":"Am J Surg"},{"issue":"35","key":"2539_CR24","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2013.50.1114","volume":"31","author":"D Han","year":"2013","unstructured":"Han D, Zager JS, Shyr Y, Chen H, Berry LD, Iyengar S, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013;31(35):4387\u201393.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2539_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757\u201367.","journal-title":"Lancet Oncol"},{"issue":"23","key":"2539_CR26","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211\u201322.","journal-title":"N Engl J Med"},{"issue":"4","key":"2539_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/00000658-199110000-00013","volume":"214","author":"DL Morton","year":"1991","unstructured":"Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 1991;214(4):491\u20139 (discussion 9-501).","journal-title":"Ann Surg"},{"issue":"4","key":"2539_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.6004\/jnccn.2017.0047","volume":"15","author":"T Strom","year":"2017","unstructured":"Strom T, Torres-Roca JF, Parekh A, Naghavi AO, Caudell JJ, Oliver DE, et al. Regional radiation therapy impacts outcome for node-positive cutaneous melanoma. J Natl Compr Canc Netw. 2017;15(4):473\u201382.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"2539_CR29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","volume":"16","author":"MA Henderson","year":"2015","unstructured":"Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16(9):1049\u201360.","journal-title":"Lancet Oncol"},{"issue":"19","key":"2539_CR30","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med"},{"issue":"11","key":"2539_CR31","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandala M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465\u201377.","journal-title":"Lancet Oncol."},{"issue":"33","key":"2539_CR32","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","volume":"38","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III Melanoma: Updated results from the EORTC 1325-MG\/KEYNOTE-054 trial. J Clin Oncol. 2020;38(33):3925\u201336.","journal-title":"J Clin Oncol."},{"issue":"19","key":"2539_CR33","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant Pembrolizumab versus placebo in resected stage III Melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med"},{"issue":"19","key":"2539_CR34","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated Melanoma. N Engl J Med. 2017;377(19):1813\u201323.","journal-title":"N Engl J Med"},{"issue":"35","key":"2539_CR35","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.18.01219","volume":"36","author":"A Hauschild","year":"2018","unstructured":"Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-Mutant stage III Melanoma. J Clin Oncol. 2018;36(35):3441\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2539_CR36","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","volume":"21","author":"R Dummer","year":"2020","unstructured":"Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020;21(3):358\u201372.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2539_CR37","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M, Atkinson V, Mandala M, Kirkwood JM, et al. Five-year analysis of adjuvant Dabrafenib plus Trametinib in stage III Melanoma. N Engl J Med. 2020;383(12):1139\u201348.","journal-title":"N Engl J Med"},{"issue":"8","key":"2539_CR38","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","volume":"31","author":"CN Owen","year":"2020","unstructured":"Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, et al. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy(). Ann Oncol Off J Eur Soc Med Oncol. 2020;31(8):1075\u201382.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"20","key":"2539_CR39","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1002\/cncr.26111","volume":"117","author":"JA Sosman","year":"2011","unstructured":"Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011;117(20):4740\u20136.","journal-title":"Cancer"},{"issue":"26","key":"2539_CR40","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517\u201326.","journal-title":"N Engl J Med"},{"issue":"5","key":"2539_CR41","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","volume":"18","author":"PA Ascierto","year":"2017","unstructured":"Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, et al. Ipilimumab 10\u00a0mg\/kg versus ipilimumab 3\u00a0mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18(5):611\u201322.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2539_CR42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","volume":"5","author":"PA Ascierto","year":"2019","unstructured":"Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 2019;5(2):187\u201394.","journal-title":"JAMA Oncol"},{"issue":"4","key":"2539_CR43","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"10105","key":"2539_CR44","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853\u201362.","journal-title":"Lancet"},{"issue":"9","key":"2539_CR45","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239\u201351.","journal-title":"Lancet Oncol"},{"issue":"13","key":"2539_CR46","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMc1509660","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(13):1270\u20131.","journal-title":"N Engl J Med"},{"issue":"14","key":"2539_CR47","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced Melanoma. N Engl J Med. 2017;377(14):1345\u201356.","journal-title":"N Engl J Med"},{"issue":"19","key":"2539_CR48","doi-asserted-by":"publisher","first-page":"389","DOI":"10.21037\/atm.2017.08.10","volume":"5","author":"E Espinosa","year":"2017","unstructured":"Espinosa E, Marquez-Rodas I, Soria A, Berrocal A, Manzano JL, Gonzalez-Cao M, et al. Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM). Ann Transl Med. 2017;5(19):389.","journal-title":"Ann Transl Med"},{"issue":"25","key":"2539_CR49","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780\u20138.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2539_CR50","doi-asserted-by":"publisher","first-page":"9512","DOI":"10.1200\/JCO.2019.37.15_suppl.9512","volume":"37","author":"G Liszkay","year":"2019","unstructured":"Liszkay G, Gogas H, Mandal\u00e0 M, Fernandez AMA, Garbe C, Schadendorf D, et al. Update on overall survival in COLUMBUS: a randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600\u2013mutant melanoma. J Clin Oncol. 2019;37(15_suppl):9512.","journal-title":"J Clin Oncol"},{"issue":"15","key":"2539_CR51","doi-asserted-by":"publisher","first-page":"9522","DOI":"10.1200\/JCO.2018.36.15_suppl.9522","volume":"36","author":"B Dreno","year":"2018","unstructured":"Dreno B, Ascierto PA, McArthur GA, Atkinson V, Liszkay G, Giacomo AMD, et al. Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation\u2013positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study. J Clin Oncol. 2018;36(15):9522.","journal-title":"J Clin Oncol."},{"issue":"12","key":"2539_CR52","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","volume":"17","author":"GV Long","year":"2016","unstructured":"Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016;17(12):1743\u201354.","journal-title":"Lancet Oncol"},{"issue":"10","key":"2539_CR53","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1001\/jamaoncol.2018.2668","volume":"4","author":"A Hauschild","year":"2018","unstructured":"Hauschild A, Larkin J, Ribas A, Dr\u00e9no B, Flaherty KT, Ascierto PA, et al. Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600-mutated metastatic melanoma: pooled analysis of 4 randomized clinical trials. JAMA Oncol. 2018;4(10):1382\u20138.","journal-title":"JAMA Oncol"},{"key":"2539_CR54","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel S, R\u00f6hmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer (Oxford, England : 1990). 2017;83:247\u201357.","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"2539_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","volume":"75","author":"L Zimmer","year":"2017","unstructured":"Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-l therapy in advanced melanoma. Eur J Cancer (Oxford, England: 1990). 2017;75:47\u201355.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"1","key":"2539_CR56","first-page":"119","volume":"19","author":"F Aya","year":"2017","unstructured":"Aya F, Fernandez-Martinez A, Gaba L, Victoria I, Tosca M, Pineda E, et al. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mexico. 2017;19(1):119\u201324.","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mexico"},{"issue":"5","key":"2539_CR57","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603\u201315.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2539_CR58","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(17)30846-X","volume":"19","author":"JA Beaver","year":"2018","unstructured":"Beaver JA, Hazarika M, Mulkey F, Mushti S, Chen H, He K, et al. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2018;19(2):229\u201339.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2539_CR59","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(12):1884\u2013901.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"4","key":"2539_CR60","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ijrobp.2017.06.2454","volume":"99","author":"PW Sperduto","year":"2017","unstructured":"Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, et al. Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (Melanoma-molGPA). Int J Radiat Oncol Biol Phys. 2017;99(4):812\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2539_CR61","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jso.21903","volume":"104","author":"N Wasif","year":"2011","unstructured":"Wasif N, Bagaria SP, Ray P, Morton DL. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol. 2011;104(2):111\u20135.","journal-title":"J Surg Oncol"},{"issue":"8","key":"2539_CR62","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","volume":"18","author":"PD Brown","year":"2017","unstructured":"Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049\u201360.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2539_CR63","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018;379(8):722\u201330.","journal-title":"N Engl J Med"},{"issue":"6","key":"2539_CR64","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11864-020-00733-z","volume":"21","author":"A Rishi","year":"2020","unstructured":"Rishi A, Yu HM. Current treatment of melanoma brain metastasis. Curr Treat Opt Oncol. 2020;21(6):45.","journal-title":"Curr Treat Opt Oncol"},{"issue":"7","key":"2539_CR65","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863\u201373.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2539_CR66","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1002\/ijc.30407","volume":"139","author":"J Rockberg","year":"2016","unstructured":"Rockberg J, Amelio JM, Taylor A, Jorgensen L, Ragnhammar P, Hansson J. Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence. Int J Cancer. 2016;139(12):2722\u20139.","journal-title":"Int J Cancer"},{"issue":"2","key":"2539_CR67","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1046\/j.1365-2133.1999.02657.x","volume":"140","author":"TJ Dicker","year":"1999","unstructured":"Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma, Scottish Melanoma Group. Br J Dermatol. 1999;140(2):249\u201354.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2539_CR68","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1200\/JCO.2003.01.091","volume":"21","author":"C Garbe","year":"2003","unstructured":"Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21(3):520\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2539_CR69","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jnci\/djq455","volume":"103","author":"Y Xing","year":"2011","unstructured":"Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103(2):129\u201342.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2539_CR70","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jaad.2016.02.1229","volume":"75","author":"S Podlipnik","year":"2016","unstructured":"Podlipnik S, Carrera C, Sanchez M, Arguis P, Olondo ML, Vilana R, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study. J Am Acad Dermatol. 2016;75(3):516\u201324.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2539_CR71","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/bjd.16833","volume":"180","author":"S Podlipnik","year":"2019","unstructured":"Podlipnik S, Moreno-Ramirez D, Carrera C, Barreiro A, Manubens E, Ferrandiz-Pulido L, et al. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma. Br J Dermatol. 2019;180(5):1190\u20137.","journal-title":"Br J Dermatol"},{"key":"2539_CR72","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/2046-4053-1-62","volume":"1","author":"MA Schroer-Gunther","year":"2012","unstructured":"Schroer-Gunther MA, Wolff RF, Westwood ME, Scheibler FJ, Schurmann C, Baumert BG, et al. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET\/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. Syst Rev. 2012;1:62.","journal-title":"Syst Rev"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02539-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-020-02539-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02539-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T18:33:43Z","timestamp":1675017223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-020-02539-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2539"],"URL":"https:\/\/doi.org\/10.1007\/s12094-020-02539-9","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"2 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MMT reports grants and personal fees from BMS; personal fees from Astra Zeneca, Novartis, Roche, MSD, Boehringer Ingelheim, Takeda, Pierre-Fabre and Bayer; non-financial support from Astra Zeneca, MSD, Boehringer Ingelheim outside the submitted work. JLM reports personal fees from Novartis, Roche, Pierre-Fabre, BMS, MSD and grants from; Merck, Roche, Abbvie, Astra Zeneca outside the submitted work. I.M.-R. has received grants as advisory board member and travel and congress accommodation from BMS, MSD, Roche, Novartis, Amgen, Pierre Fabre, Merck Serono, Sanofi, Regeneron, Incyte, AstraZeneca, and Bioncotech.\u00a0LCM reports grants and personal fees from BMS, Roche, MSD-Merck, and Amgen, personal fees from Pierre Fabre, Novartis, and grants from Celgene, outside the submitted work. EE reports personal fees from BMS, MSD, Novartis, Pierre Fabre, and Roche. MGC reports personal fees from NOVARTIS, BMS, and Roche. AB reports personal fees and non-financial support from BMS, MSD, Roche, Novartis, Sanofi, and Merck-Pfizer, and personal fees from Pierre Fabre and Incyte, outside the submitted work. KM, EPR, and EMC have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}